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Antiangiogenic therapy with bevacizumab has shown varying results in breast cancer clin-
ical trials. Identifying robust biomarkers for selecting patients who may benefit from such
treatment and for monitoring response is important for the future use of bevacizumab.
Two established xenograft models representing basal-like and luminal-like breast cancer
were used to study bevacizumab treatment response on the metabolic and gene expression
levels. Tumor samples were obtained from mice treated with bevacizumab, doxorubicin or
a combination of the two drugs, and high resolution magic angle spinning magnetic reso-
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MetabolomicsCombination treatment with bevacizumab showed the strongest growth inhibiting effect
in basal-like tumors, and this was reflected by a significant change in the metabolomic
and transcriptomic profiles. In the luminal-like xenografts, addition of bevacizumab did
not improve the effect of doxorubicin. On the global transcriptomic level, the largest
gene expression changes were observed for the most efficient treatment in both models.
Glycerophosphocholine showed opposite response in the treated xenografts compared
with untreated controls; lower in basal-like and higher in luminal-like tumors. Comparing
combination therapy with doxorubicin monotherapy in basal-like xenografts, 14 genes
showed significant differential expression, including very low density lipoprotein receptor
(VLDLR) and hemoglobin, theta 1 (HBQ1). Bevacizumab-treated tumors were associated
with a more hypoxic phenotype, while no evidence was found for associations between
bevacizumab treatment and vascular invasion or tumor grade.
This study underlines the importance of characterizing biological differences between sub-
types of breast cancer to identify personalized biomarkers for improved patient stratifica-
tion and evaluation of response to therapy.
ª 2012 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.1. Introduction High PCho levels or high PCho/GPC ratio with correspondingTargeting tumor vasculature has evolved as an attractive
strategy to treat solid tumors. One implemented strategy for
several cancers is antiangiogenic treatment utilizing a VEGF
targeting antibody (bevacizumab) (Braghiroli et al., 2012). Lim-
ited benefit in progression free survival (PFS) and lack of ben-
efit in overall survival (OS) reported from clinical trials have
raised questions about the relevance of bevacizumab for ad-
vanced breast cancer (Burstein, 2011). In 2010, FDA has re-
voked the breast cancer indication for bevacizumab.
However, recent results have indicated that prolonged bevaci-
zumab administration in metastatic breast cancer patients
may give a benefit in OS (Bear et al., 2012; Smith et al., 2011;
VonMinckwitz et al., 2012). The clinical utility of bevacizumab
in breast cancerwill depend on the identification of subgroups
of patients who are likely to benefit from antiangiogenic
therapy (Schneider and Sledge, Jr. 2011). Several potential bio-
markers have been proposed, including VEGFR polymor-
phisms, and VEGF, PDGFR-b and VCAM1 expression
(Schneider et al., 2008; Yang et al., 2008; Jubb et al., 2011;
Baar et al., 2009), but none have been established as reproduc-
ible. Hence, the aim of this study was to investigate the biol-
ogy of treatment response and possible resistance effects by
combining metabolomics and transcriptomics of breast can-
cer xenograft models in order to identify response biomarker
candidates for later verification in a clinical setting.
The tumor metabolome is known to be highly affected by
extracellular factors such as the microenvironment, pH, oxy-
gen, nutrients and drugs. Thus, metabolomic techniques
have the potential to be more sensitive in monitoring treat-
ment than other approaches such as measuring levels of
RNA or proteins. Several metabolomic markers of treatment
response have been suggested, including total choline
(tCho), measured using in vivo MRS (Jagannathan et al., 2001;
Meisamy et al., 2004), and phosphocholine (PCho), glycero-
phosphocholine (GPC) and lactate, measured using higher res-
olution MRS (Beloueche-Babari et al., 2010; Podo et al., 2011).expression levels of genes involved in choline metabolism
have been associated with malignancy and aggressiveness
in both triple negative and ER positive breast cancer cell lines
(Eliyahu et al., 2007; Glunde et al., 2004; Katz-Brull et al., 2002).
On the other hand, high levels of GPC have been associated
with ER negative tumors in studies of human breast carcino-
mas (Barzilai et al., 1991; Giskeodegard et al., 2010), suggesting
that in vitro studies do not capture the complexity of tumor
metabolism.
In vivomodels are valuable tools for studying treatment re-
sponse mechanisms since human carcinomas can be studied
surrounded by a relevant microenvironment (Vargo-Gogola
and Rosen, 2007). Two directly grafted orthotopic xenograft
models representing basal-like and luminal-like breast cancer
have previously been established and characterized at the
transcriptomic and metabolomic levels (Bergamaschi et al.,
2009; Lindholm et al., 2012; Moestue et al., 2010). The
luminal-like model had a high PCho/GPC ratio while the
basal-like model showed the opposite. The same differences
were also found in clinical tumor samples, suggesting that
these two models are relevant for studies of metabolism and
treatment response in these two types of breast cancer
(Moestue et al., 2010).
Recently, treatment studies in these models demonstrated
that the basal-like model showed significantly improved
response to bevacizumab and doxorubicin in combination
compared with doxorubicin alone, while the luminal-like
model responded equally well to doxorubicin with or without
antiangiogenic therapy (Lindholm et al., 2012). Metabolomic
and transcriptomic analysis of tumor tissue from these exper-
iments was performed using high resolution magic angle
spinning magnetic resonance spectroscopy (HR MAS MRS)
and gene expression microarrays.
We demonstrate that GPC is a promising biomarker on the
metabolomic level and that several gene transcripts are asso-
ciated with bevacizumab responses in the responding basal-
like tumors.
Figure 1 e Schematic illustration of the study design. Schematic illustration of the treatment experiments and metabolomic and transcriptomic
analyses. Abbreviations: bev D dox: bevacizumab D doxorubicin; rep: replicates; HR MAS MRS: high resolution magic angle spinning magnetic
resonance spectroscopy.
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2.1. Xenograft models and treatment
Two orthotopic xenograft models, a basal-like (MAS98.12) and
a luminal-like (MAS98.06), have been established by directly
grafting human primary breast cancer tissue into SCID
mice and serially transplanted, as previously described
(Bergamaschi et al., 2009). An overview of the experimental
procedure in the current work is illustrated in Figure 1. Ani-
mals from the two xenograft models were randomly assigned
to different treatment groups after the tumor diameter
reached approximately 5 mm. For each model, tumors were
collected from animals that were untreated or treated repeat-
edly with bevacizumab at day 1, 4 and 7 (5mg/kg), doxorubicin
(8 mg/kg) at day 1 only, or a combination of the two therapies
(n ¼ 6 tumors for each group), as described in (Lindholm et al.,
2012). Animals were sacrificed and tissue harvested at either
day 3 or 10 after treatment, in triplicates within each treat-
ment group, resulting in 24 tumor samples from each of the
models. In addition, untreated and bevacizumab treated
luminal-like xenografts not fed with estradiol were included
for comparison (n ¼ 12). Tumor tissue from all animals was
stored in liquid nitrogen and separate tumor pieces wereused for HR MAS MRS and gene expression microarray analy-
sis. Out of the 48 samples from the estrogen fed animals ana-
lyzed with both experimental techniques, 33 were from the
same tumor, 11 were from the samemouse but from different
tumors (from bilateral implantations), and 4 were from differ-
ent mice. The 12 tumors from animals not receiving estrogen
supplement were included in the gene expression analysis for
normalization purposes. All procedures and experiments in-
volving animals were approved by the National Animal Re-
search Authority and were conducted according to the
regulations of the Federation of European Laboratory Animal
Science Association (FELASA).2.2. HR MAS MRS experiments and data processing
HR MAS MRS experiments and data preprocessing were per-
formed on a Bruker Avance DRX600 spectrometer equipped
with a 1H/13C HR MAS probe (Bruker BioSpin Corp.) as previ-
ously described (Moestue et al., 2010). Spectral assignments
were performed based on a previous HR MAS MRS study of
breast cancer lesions (Sitter et al., 2002). The regions repre-
senting the internal and electric standards TSP and ERETIC,
as well as the metabolites creatine, choline, phosphocholine
(PCho), glycerophosphocholine (GPC), taurine (Tau), glycine
M O L E C U L A R O N C O L O G Y 7 ( 2 0 1 3 ) 1 3 0e1 4 2 133(Gly), and lactate (Lac) were selected for quantification in all
spectra. Peak areas were calculated by polynomial curve fit-
ting (PeakFit v 4, Systat Software Inc) with a combination of
Gaussian and Lorentzian line-shapes (Voigt function). Con-
centrations of tissue metabolites were calculated relative to
the ERETIC signal as previously described (Moestue et al.,
2010).2.3. Gene expression microarray experiments and
normalization
Total RNA from all 60 tumor pieces was extracted using the
TRIzol reagent (Invitrogen) according to the manufacturer’s
protocol. Total RNA concentration wasmeasured using Nano-
Drop (NanoDrop Technologies) and quality assessed using
2100 Bioanalyzer (Agilent Technologies). 700 ng total RNA
was amplified, labeled using cy3-CTP and hybridized to one-
color Agilent Technologies 4  44K Whole Human Genome
Microarrays, as previously described (Moestue et al., 2010).
Data were extracted from the scanned images using Feature
Extraction (FE) software (Agilent Technologies) version
10.1.1.1 and protocol GE1-v5_10_Apr08 for mRNA and further
processed and normalized using R (v2.10.1) and Bioconductor
(Gentleman et al., 2004). Data from all samples were included
in normalization and statistical analysis to increase power.
Data were detrended for multiplicative effects and log2 trans-
formed. Data from control probes, probes with inferior quality
(feature outliers from FE) for more than 20 percent of the ar-
rays, and probes that were flagged as present on less than 20
percent of the arrays were omitted from the analysis. The av-
erage value of duplicate probes was used to represent each
unique probe. Missing data were imputed using k-nearest
neighbors (k ¼ 10) (Troyanskaya et al., 2001), and all data
were quantile normalized. For transcripts (based on Gene-
Name as provided by Agilent Technologies) represented by
multiple different probes, the probe with the highest inter-
quartile range (IQR) was chosen to represent each transcript.
The normalized dataset included data for 28150 unique
mRNA transcripts on 60 microarrays from the tumor biopsies;
24 from MAS98.12 animals, 24 from MAS98.06 animals fed
with estradiol and 12 from MAS98.06 animals not fed with es-
tradiol. The microarray data have been deposited in NCBI’s
Gene Expression Omnibus and are accessible through GEO Se-
ries accession number GSE37543 (http://www.ncbi.nlm.nih.-
gov/geo/query/acc.cgi?acc¼GSE37543).2.4. Statistical analysis
2.4.1. Analysis of metabolomic profiles
The quantified concentrations of the specificmetabolites were
used to assess whether any of these was affected by the treat-
ments. Concentrations of each metabolite were modeled sep-
arately for each of the two xenografts using a twoway ANOVA
with interaction, the covariates treatment and days treated as
factors. This analysis was used for pairwise comparisons be-
tween each treatment with no treatment at day 3 and day
10, respectively. For each day, the expected number of false
positives is 42 * 0.05 ¼ 2.1. The number of tests with nominal
p-values <0.05 is 17.2.4.2. Analysis of gene expression profiles
Gene expression data were analyzed for differences between
treatments in the two xenograft models. Exploiting the facto-
rial design of the experiments, the Bioconductor package
Limma was used to model the expression levels of each tran-
script in the microarray data as a function of all combinations
of the different days and treatments, equivalent of a two way
ANOVA with interaction (Smyth, 2004). Data from the two xe-
nograft models were modeled separately, and treatment and
day were used as factors. An observed batch effect in the
microarray data, corresponding to amplification date,was cor-
rected for in the model by using the blocking factor imple-
mented in Limma (Smyth et al., 2005). All pairwise
comparisons between treated and untreated xenografts from
the samedaywere analyzedby relevant contrasts to themodel
as described by Smyth (Smyth, 2011). Additionally, the combi-
nation treatment was compared with doxorubicin monother-
apy. The test statistics were Empirical Bayes modified and p-
values were corrected for multiple testing using Benjamini
Hochberg false discovery rate (FDR) for each pairwise compar-
ison separately (Benjamini and Hochberg, 1995; Smyth, 2004).
This analysis was performed on all gene transcripts and on
a gene set of 105 genes representing phospholipidmetabolism
(involved in KEGG glycerophospholipid pathway, choline
transport, or choline and glycine metabolism), as previously
described (Moestue et al., 2010). To analyze whether any bio-
logical processes were enriched among the genes most differ-
entially expressed between treated and untreated xenografts,
GOrilla was used (Eden et al., 2009). For each comparison, lists
of all 28150 transcripts in the microarray data were ranked
according to fold change and analyzed for GO-term enrich-
ment towards the top of the lists.
2.4.3. Using gene expression signatures as surrogate
measures
Published microarray based gene expression signatures in-
cluding genomic grade index (GGI) (Sotiriou et al., 2006), a hyp-
oxia classifier (Chi et al., 2006) and a vascular invasion
signature (Mannelqvist et al., 2011) were used to study differ-
ences in specific biological features in relation to bevacizumab
treatment effects and possible induced resistance. Using
scores from each of these signatures, comparisons between
the two xenograft models and between the treatments were
performed using ANOVA (similar to the analysis for assessing
differences in metabolite concentrations). The original probes
in the GGI (Affymetrix ID) and hypoxia gene signatures (Clone
IDs) were matched to Agilent Probe IDs using the R-package
BiomaRt (Durinck et al., 2005), while the genes in the vascular
invasion signature were matched by gene symbol directly. To
analyze differences in aggressiveness between the untreated
basal-like and luminal-like tumors as well as between treated
and untreated tumors for each of the twomodels, the gene ex-
pression based GGI was used as a surrogatemeasure. Raw GGI
scores were calculated by using a weighted average of the ex-
pression levels of genes shown to differentiate between grade
I and III breast carcinomas (Sotiriou et al., 2006) and used di-
rectly. For hypoxia assessment in the tumor samples, a set
of genes induced by hypoxia in cultured epithelial cells were
investigated (Chi et al., 2006). For each probe for each sample,
the median expression value across all samples was
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the median expression of the hypoxia related genes for each
sample. A recently published vascular invasion signature
was used as surrogate marker for vascular invasion of tumor
epithelial cells (Mannelqvist et al., 2011). This gene signature
represents differences in gene expression between vascular
invasion positive and negative endometrial tumors, based
on staining for presence of tumor cells in blood vessels. Data
for the selected genes were mean centered across all samples,
and the published log fold change of each gene was analyzed
for nonzero correlations with the expression of the matched
genes for each xenograft sample. The correlation coefficients
were used as scores to compare vascular invasion between
the xenograft models and treatments.
2.4.4. Analysis of phospholipid metabolism gene expression
in a patient cohort
To assess whether the distinct expression patterns of genes
involved in phospholipid metabolism previously observed in
the two xenograft models (Moestue et al., 2010) are represen-
tative of basal-like and luminal-like cancer, amicroarray data-
set from a patient cohort of 115 breast carcinomas was
analyzed (Enerly et al., 2011). Since the patient and xenograft
microarray data were from the same platform (Agilent Tech-
nologies 4  44K Whole Human Genome Microarrays), the
probes representing the 105 phospholipid metabolism genes
were exactlymatched between the two datasets. The assigned
intrinsic subtypes of the patient tumors were used to select
the 16 basal-like tumors and 61 luminal tumors in the dataset
(including both luminal A and luminal B). Data were centered
across genes and a heatmap was generated by clustering of
the 105 genes and 77 samples using Pearson’s correlation
and average linkage. Limma was used to test for differences
between the two groups in the patient data, and generated
(modified) t-statistics were compared with those from the xe-
nograft data (as previously published (Moestue et al., 2010))
using Pearson’s correlation test.3. Results
3.1. Metabolomic response to treatment
Quantifiedmetabolite concentrationswere used to analyze dif-
ferences inCho,GPC, PCho, tCho, Tau,Cre, Gly and Lac between
treated and untreated tumors from both models (See
Supplementary Figure 1). The basal-like xenograft represented
a bevacizumab responderwhile the luminal-like xenograft rep-
resented a non-responder to this drug. Therefore, changes ob-
served after treatment with bevacizumab in basal-like and not
in luminal-like tumorswereofparticular interest as thesecould
have the potential of being used in treatment monitoring. In-
deed, GPC is potentially such a marker, as it showed opposite
patterns of response to treatment in the two differently
responding xenograft models (Figure 2). In basal-like tumors,
GPC concentrations were significantly lower after any of the
three treatment modalities at day 10, and there was a similar
trend at day 3. This was in contrast to luminal-like tumors,
where GPC concentrations were significantly higher in thedoxorubicin and combination treated tumors compared with
untreated tumors at day 10 andno significant changeswere ob-
served for bevacizumab monotherapy, indicating that this re-
sponse is triggered by doxorubicin treatment. PCho on the
other hand, showed either no change in concentrations or
tended to increase in treated animals of both models
(Figure 2). In the basal like model, there was no change in
tCho, in contrast to the luminal-likemodel demonstratinga sig-
nificant increase after the combination treatment compared
withno treatment.Thus, thevalueof tChoasa responsemarker
by using in vivoMRSmay be reduced due to these differences in
patternsofcholinederivativesbetween tumorsubgroups.Table
1 summarizes all metabolites that displayed either higher or
lower levels after the three different treatment regimes at day
10. None of the other metabolites demonstrated predictive
value.
3.2. Gene expression response to the most efficient
treatment
The most efficient treatment, measured as growth delay in
each of the two models, was associated with the largest mag-
nitude of gene expression changes at day 10 (Figure 3). Signif-
icantly enriched biological processes were also found among
the most differentially expressed genes. For the basal-like
model, the largest transcriptional response was seen in tu-
mors from animals given the combination therapy, and 40
transcripts showed significantly different levels compared
with untreated tumors; 38 at higher expression levels (the
most significant being HOXB13, PPP1R3C, TMEM45A) and 2
genes at lower expression levels (SLC2A12 and KRT5)
(Figure 3A and Supplementary Table 1). Furthermore, when
comparing combination treatedwith doxorubicin only treated
basal-like tumors, 14 transcripts showed significantly differ-
ent expression; 8 higher expressed, the most significant being
VLDLR, PPFIA4 and MCHR1, and 6 lower expressed, the most
significant being DAB1, HBQ1 and ACCN1 (Table 2). Five of
these genes (VLDLR, PPFIA4, MCHR1, PPP1R3C and CHI3L1)
were overlapping with the 40 genes which showed signifi-
cantly different expression between combination treatment
and no treatment (indicated in bold in Figure 3A). The GO-
term “muscle contraction” was enriched among the tran-
scripts higher expressed in the combination treated versus
both the doxorubicin only treated and untreated basal-like tu-
mors (Supplementary Table 2). In addition, several immune
process related GO-terms such as “immune response”, “in-
flammatory response” and “response to cytokine stimulus”
were enriched among the transcripts that were lower
expressed in the combination treated when compared with
doxorubicin treated basal-like tumors. However, expression
changes of such genes in xenograft tumors are difficult to in-
terpret, since the host animals are immunocompromised.
For the luminal-like model, the largest response was ob-
served in tumors treated with doxorubicin monotherapy, and
380 transcripts showed significantly different expression com-
pared with the untreated animals. Of these, 201 were higher
expressed, themost significant being EGF, RARRES3 andCAPSL.
Lower expression levels were seen in 179 genes, the most sig-
nificant being HBA2, HBA1 and KCNK5 (the top 100 genes are
shown in Figure 3B and the full list is given in Supplementary
tnemtaerT
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Figure 2 e Changes in glycerophosphocholine and phosphocholine reflect response to treatment. Concentrations of glycerophosphocholine (GPC)
and phosphocholine (PCho) at day 10 plotted for each xenograft model and colored according to treatment (n [ 3 animals per group). Significant
differences in mean concentration between treated and untreated tumors are indicated with the associated nominal p-values. Abbreviations:
bev D dox: bevacizumab D doxorubicin.
M O L E C U L A R O N C O L O G Y 7 ( 2 0 1 3 ) 1 3 0e1 4 2 135Table 3). In doxorubicin treated versus untreated luminal-like
tumors, GO-terms such as “type I interferon-mediated signal-
ing pathway”, “muscle contraction” and “muscle filament slid-
ing” were significantly enriched among the transcripts that
were higher expressed. Among the transcripts that were lower
expressed, the terms “DNA replication”, “DNA strand elonga-
tion involved in DNA replication” and “ncRNA processing”
were significantly enriched (Supplementary Table 2), which is
in agreement with the proposed mechanism of doxorubicin
of targeting topoisomerase II.
3.3. Gene expression signatures as surrogate markers
for adaptive resistance
Evasive or adaptive resistance mechanisms to antiangiogenic
treatment have been suggested, such as increased aggres-
siveness/invasiveness or recruitment of bone marrow-
derived cells due to increased hypoxia and lack of nutrients
(Bergers and Hanahan, 2008). The published gene expression
signatures GGI (Sotiriou et al., 2006), hypoxia (Chi et al., 2006)and vascular invasion (Mannelqvist et al., 2011) were used
as surrogate markers for the extent of aggressiveness, hyp-
oxia and vascular invasion by tumor epithelial cells,
respectively.
A score for each of the three signatures was calculated for
each sample. These scores were compared between the treat-
ments and no treatment at each day (Figure 4). Gene signa-
ture scores were also compared between the two models
using the untreated tumors (results not shown). Lower GGI
scores were observed after treatment with combination of
bevacizumab and doxorubicin in both xenograft models at
day 10, and a significant decrease was also observed for the
basal-like tumors after bevacizumab monotherapy. This sug-
gests that bevacizumab treatment reduced some aggressive
features of these tumors. There was not significant evidence
of differences in GGI between the two untreated xenograft
models. Notably, a significantly higher GGI was observed in
the doxorubicin treated basal-like tumors at day 3 compared
with untreated tumors. Using the hypoxia gene signature,
hypoxia scores increased in the basal-like model after
Table 1 e Metabolomic response to treatment. Overview of metabolites that displayed significantly (nominal p-values < 0.05) different mean
concentrations in treated compared with untreated xenograft models at day 10. Arrows indicate whether the concentration of each metabolite was
higher ([) or lower (Y) after treatment.
Xenograft Metabolites Doxorubicin Bevacizumab Bevacizumab þ doxorubicin
Basal-like Cholines GPCaY***, tChobY* Pchoc[*, GPCY* GPCY*
Other metabolites GlyY***, CreeY***, TaudY* GlyfY*, CreY**, TauY*
Luminal-like Cholines GPC[**, tCho[* PCho[*, GPC[*, tCho[**
Other metabolites TauY*
*p < 0.05, **p < 0.01, ***p < 0.001.
a GPC: glycerophosphocholine.
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ment at both day 3 and 10. A significant increase was also ob-
served in bevacizumab treated luminal-like tumors at day 3.
The untreated luminal-like tumors had significantly higher
hypoxia scores than the untreated basal-like tumors, sug-
gesting that the luminal-like tumors were more hypoxic
than the basal-like tumors. When comparing vascular inva-
sion gene signature scores between the two models, basal-
like tumors showed significantly higher baseline scores.
While no significant differences in vascular invasion scores
between treatments were observed for the basal-like model,
significantly higher scores were observed for luminal-like tu-
mors treated with doxorubicin and combination treatment at
day 10. This result suggests that vascular invasion could be
increased in the doxorubicin treated luminal-like tumors,
while there is no evidence for bevacizumab inducing such
an effect.
3.4. Comparison of phospholipid metabolism between
xenografts and human carcinomas by means of gene
expression
In a previous study, we showed that genes involved in choline
transport, phospholipid metabolism, and glycine metabolism
were differentially expressed between the basal-like and
luminal-like xenograft models, and that levels of expression
corresponded to metabolomic changes (Moestue et al., 2010).
Using these same genes to analyze differences between treated
and untreated tumors, the LCAT gene (encoding the enzyme
lecithin-cholesterol acyltransferase) showed significantly
higher levels of expression in combination treated versus un-
treated basal-like tumors at day 10. Therewere no other signif-
icant changes in expression of genes involved in phospholipid
metabolism. The observed metabolomic responses of choline
derivatives may reflect intrinsic differences in phospholipid
metabolism between themodels. To assess whether themeta-
bolic phenotypes of the xenograft models are intrinsic proper-
ties of basal-like and luminal-like tumors on the gene
expression level, a human breast tumor microarray dataset
was used to compare expression differences of genes involved
in phospholipid metabolism between these two biologically
distinct subgroups of breast cancer (Supplementary
Figure 2A). A clustering analysis revealed great similaritybetween basal-like tumors, while the luminal-like tumors
weremoreheterogeneous in their expression of genes involved
in phospholipid metabolism. Analyses of differential expres-
sion of these genes between basal-like and luminal-like tumors
were compared between human and xenograft tumors. The
correlation between these two analyseswas found to be signif-
icant (rho¼ 0.34,p-value< 4.1 104) (Supplementary Figure2B
and C). Themost significant differences in gene expression ob-
served both in the xenograft and human basal-like versus
luminal-like tumors included higher expression of PLA2G4A,
PLCG2 and AGPAT4; and lower expression of GPD1L, PLCD4
and ETNK2.4. Discussion
Antiangiogenic therapy such as bevacizumabmay bemore ef-
ficient in certain subgroups of breast cancer. To exploit the po-
tential of bevacizumab as a breast cancer drug, individualized
biomarkers are needed to select patients and assess treatment
response. Metabolomic biomarkers are especially attractive
because they have the potential of being measured in vivo
allowing treatment monitoring and adaptation of given ther-
apy according to response. In the present study, the metabo-
lite with highest potential as a biomarker for monitoring
response to bevacizumab was GPCwhich showed opposite re-
sponse patterns in the two xenografts; lower in the treated
basal-like tumors and higher in treated luminal-like tumors
compared with untreated controls. PCho on the other hand,
showed either no difference or an increase in concentration
in both models. This underlines the importance of character-
izing subtypes of breast cancer separatelywhen evaluating re-
sponse markers for treatment monitoring. Clinical 1-H in vivo
MRS of breast tumors detects tCho which is the sum of GPC,
PCho and Cho signals. Opposite behavior of GPC and PCho in
response to treatment, as observed using ex vivo HR MAS
MRS for the basal-like tumors, may impact the utility of
tCho as a response marker. However, with increasing field
strengths and the possibility of implementing 31-P coils in
clinical magnets, the GPC and PCho peaks could be separated
in the spectra obtained in vivo (Morse et al., 2007). Thus,
metabolomic biomarkers such as GPC could in the future be
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Figure 3 e Subtype-specific response to treatment reflected in transcriptomic profiles. Heatmaps of significantly differentially expressed genes
(FDR < 0.05) at day 10 between untreated xenografts and xenografts given the most efficient treatment for each model: (A) combination
treatment for basal-like and (B) doxorubicin for luminal-like xenografts (only the top 100 transcripts are shown). Each gene was mean centered and
clustering of samples and genes was performed using Euclidian distance and complete linkage. The color coding is based on scaled expression
values where each gene is scaled to have mean zero and standard deviation one. Transcripts that were also significantly differentially expressed
when comparing combination treated with doxorubicin treated basal-like tumors (Listed in Table 2) are indicated with bold gene symbols in A.
Abbreviations: bev_dox: bevacizumab D doxorubicin.
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Table 2 e Additional transcriptomic response to bevacizumab in basal-like xenografts. Transcripts with significant (FDR < 0.05) difference in
mean expression levels between basal-like tumors that received combination of bevacizumab and doxorubicin compared with those that received
doxorubicin monotherapy.
Probe name Gene name Description logFCa t p-value FDRb
Higher expression levels in combination treated tumors
A_23_P43476 VLDLR Very low density lipoprotein
receptor, transcript variant 1
1.4 7.8 1.7E-07 0.0047
A_23_P420692 PPFIA4 Protein tyrosine phosphatase,
receptor type, f polypeptide
(PTPRF), interacting protein
(liprin), alpha 4
1.0 6.6 1.9E-06 0.013
A_23_P139166 CB959193 CB959193 AGENCOURT_13778270
NIH_MGC_184 cDNA clone
IMAGE:30351353 50
1.9 6.2 4.7E-06 0.019
A_23_P211543 MCHR1 Melanin-concentrating hormone
receptor 1
0.8 6.0 6.2E-06 0.022
A_23_P35414 PPP1R3C Protein phosphatase 1, regulatory
(inhibitor) subunit 3C
1.6 5.9 8.2E-06 0.026
A_23_P137665 CHI3L1 Chitinase 3-like 1 (cartilage
glycoprotein-39)
0.93 5.8 9.7E-06 0.027
A_32_P128586 DA727827 DA727827 NT2RM1 cDNA
clone NT2RM1001124 50
0.86 5.8 1.2E-05 0.029
A_23_P117851 CPLX3 Complexin 3 0.93 5.6 1.6E-05 0.032
Lower expression levels rin combination treated tumors levels
A_23_P23850 DAB1 Disabled homolog 1 (drosophila) 1.7 6.6 1.9E-06 0.013
A_23_P49254 HBQ1 Hemoglobin, theta 1 1.6 6.7 1.5E-06 0.013
A_32_P159612 ACCN1 Amiloride-sensitive cation
channel 1, neuronal (degenerin)
1.7 6.4 3.1E-06 0.017
A_24_P416097 ENST00000336999 UNC45 homolog A (UNC-45A)
(Smooth muscle cell-associated
protein 1)
1.2 6.3 3.6E-06 0.017
A_24_P75190 HBD Hemoglobin, delta 2.0 5.7 1.3E-05 0.030
A_23_P29939 SNCA Synuclein, alpha (non A4
component of amyloid precursor),
transcript variant NACP112
2.0 5.7 1.4E-05 0.030
a logFC: log2 fold change.
b FDR: false discovery rate.
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and for monitoring response to treatment.
On the gene expression level, this study suggests that the
most significant gene expression changes occur in tumors
which benefit themost from a given treatment, i.e. the combi-
nation of bevacizumab and doxorubicin for basal-like and
doxorubicin monotherapy for luminal-like tumors. A similar
trend was also found tumors at the proteomic level, i.e. the
most effective treatment was linked to higher kinase activity
at day 10 (Lindholm et al., 2012). The transcripts expressed
at significantly different levels between the combination and
doxorubicin treated tumors in the basal-like xenograft model
(Table 2) are particularly interesting since these may suggest
biological mechanisms for the additional effect of bevacizu-
mab. Five of these genes were also significantly higher
expressed in the bevacizumab and doxorubicin combination
treated compared with untreated tumors, including VLDLR
and CHI3L1 which have both previously been associated
with angiogenesis (Oganesian et al., 2008; Saidi et al., 2008;
Nishikawa and Millis, 2003). Of the transcripts which showed
reduced expression after the combination treatment com-
pared with doxorubicin, two hemoglobins (HBQ1 and HBD)
were represented. It could be speculated that the genesshowing higher expressionmay represent adaptive resistance
processes while the lower expressed genes could represent
changes in composition of different cell types in the tumors
due to the antiangiogenic effects of bevacizumab. It should
however be noted that all measurements in this study are
based on bulk tumors from the mice, using human specific
microarrays, and cross hybridization of mouse specific genes
from the stromal compartment cannot be ruled out.
Focusing solely on genes involved in phospholipid metab-
olism (Moestue et al., 2010), LCAT was the only gene found
to be significantly differentially expressed in response to
treatment. LCAT has both cholesterol and phosphatidylcho-
line (PtdCho, also called lecithin) acetyltransferase activity
and may thus catalyze the same reaction as phospholipase
A2. The increase in expression of LCAT in combination treated
basal-like tumors may be counterintuitive to the decrease in
GPC as measured by HR MAS MRS. However, the increase in
LCAT levels could e.g. be due to feedback mechanisms rather
than exerting a direct effect on the levels of GPC. The apparent
lack of transcriptional response of genes involved in phospho-
lipid metabolism shows that the observed responses in cho-
line derivatives are not necessarily coupled to changes at the
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Figure 4 e Changes in gene expression signatures after treatment. Barplots of scores from the three gene expression signatures genomic grade index
(GGI) (Sotiriou et al., 2006), hypoxia (Chi et al., 2006), and vascular invasion (Mannelqvist et al., 2011) for A) basal-like and B) luminal-like
xenograft models (each bar represents n [ 3 replicates). The scores were scaled across all samples to make them comparable and significant
differences in mean scores between treated and untreated tumors at each day are indicated with the associated nominal p-values. Abbreviations:
bev D dox: bevacizumab D doxorubicin.
M O L E C U L A R O N C O L O G Y 7 ( 2 0 1 3 ) 1 3 0e1 4 2 139enzymatic activity are regulated at the post-translational
level. Also, the distinct gene expression patterns of phospho-
lipid metabolism genes found in the untreated basal-like and
luminal-like xenografts correlated with those of human
breast tumors (Supplementary Figure 2), supporting that the
differences in phospholipid metabolism may be an intrinsic
characteristic of basal-like and luminal-like breast cancer. In-
terestingly, the PLA2 coding gene PLA2G4A was one of the
most significantly differentially expressed genes between
basal-like (higher) and luminal-like (lower) for both xenografts
and human tumors. PLA2G4A has been reported to be lower
expressed in breast cancer cells concomitant with low GPClevels compared with normal epithelial breast cells (Glunde
et al., 2004), and has been found to be inversely correlated
with ESR1 expression in breast cancer cell lines and human
breast carcinomas (Caiazza et al., 2011). Thus, targeting
PLA2G4A could perhaps be an interesting approach in treat-
ment of basal-like cancers.
Bevacizumab associated changes in expression of genes in-
volved in biological processes associated with adaptive treat-
ment resistance are of particular interest in light of the
limited success of bevacizumab in breast cancer clinical trials.
Two different modes of resistance to antiangiogenic therapy
have been suggested (Bergers and Hanahan, 2008), and
M O L E C U L A R O N C O L O G Y 7 ( 2 0 1 3 ) 1 3 0e1 4 2140following these definitions the luminal-like xenograft model
may represent an intrinsic non-responder while the basal-
like xenograft model may represent a responder which could
develop adaptive resistance. The observed bevacizumab asso-
ciated decrease in genomic grade index (GGI) for both models
(Figure 4) is contradictory to claims that antiangiogenic ther-
apy may increase tumor aggressiveness (Kerbel, 2009; Paez-
Ribes et al., 2009). However, bevacizumab associated increases
in hypoxia gene signature scores were observed, especially in
the basal-like xenograft model (Figure 4). Increased hypoxia
has been linked to invasiveness and metastasis (Young and
Hill, 1990), and has been proposed to induce adaptive resis-
tance to antiangiogenic therapies (Du et al., 2008). It is worth
noting that aldehyde dehydrogenase 2 family (ALDH2), which
was among themost significantly higher expressed genes after
combination treatment in basal-like xenografts (Figure 3), has
in addition to being involved in many metabolic pathways
been linked to hypoxia (Milosevic et al., 2007).
A possible indication of treatment induced invasiveness
was enrichment of the GO-term “muscle contraction” (includ-
ing genes such as myosin and actin) when comparing the
combination treated with untreated basal-like tumors or
with doxorubicin only treated tumors (Supplementary Table
2). A suggested adaptive resistance mechanism is in fact tu-
mor cell migration to more vascularized areas (Rubenstein
et al., 2000; Du et al., 2008). However, similar GO-terms were
also enriched among geneswith higher expression after doxo-
rubicin monotherapy of the luminal-like xenografts, contra-
dicting that this change is associated specifically with
bevacizumab treatment. Finally, the limitations of this study,
including only two xenograft models with three replicates in
each treatment group at each day should be kept in mind.
However, these models have been shown to be representative
for basal-like and luminal-like breast cancer, and the results
presented in this study are thus likely to be relevant for these
subtypes of breast cancer.
In summary, this study has highlighted how subtype spe-
cific response to bevacizumab was reflected on the metabolo-
mic and transcriptomic levels. The biological connection
between themolecular response at themetabolomic and tran-
scriptomic level was not evident, which underlines the com-
plementary nature of the information retrieved from these
two types of analyses. Importantly, the results from this study
support the necessity of patient stratification with respect to
biologically relevant subgroupswhen searching for biomarkers
in preclinical as well as clinical breast cancer trials. Results
from different clinical trials of bevacizumab in non-
metastatic breast cancer, have reported that both ER positive
cancers (Bear et al., 2012) and triple negative cancers (Von
Minckwitz et al., 2012)may benefit from the addition of bevaci-
zumab to chemotherapy. Clearly, biological andmolecular fea-
tures apart from the more traditional histopathological
subtype definition may determine whether a tumor is respon-
sive to bevacizumab and in which combinatorial regimen an
optimal efficacymay be reached. Also, biomarkerswith the po-
tential to predict or monitor treatment responsemay be found
across subtypes. Thus, new xenograftmodels representing the
tumorheterogeneity of basal-like and luminal-like cancers and
carefullyplanned clinical trialswill be important for investigat-
ing the biology of bevacizumab response in breast cancer.Acknowledgments
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